Calcified Tissue International

, Volume 49, Issue 1, pp 17–19 | Cite as

Synthetic human calcitonin in postmenopausal osteoporosis: A placebo-controlled, double-blind study

  • Sverker Ljunghall
  • Per Gärdsell
  • Olof Johnell
  • Karin Larsson
  • Erik Lindh
  • Karl Obrant
  • Ingemar Sernbo
Clinical Investigations

Summary

A placebo-controlled, double-blind study was carried out over 4 months to evaluate two doses of synthetic human calcitonin (0.25 and 0.125 mg) given s.c. three times per week. Enrolled were 60 women, aged 56–82 years, who had experienced a vertebral fracture due to low-energy trauma within the preceding year. During active treatment there was within the first month a dose-dependent decrease of the indices of bone resorption (fasting urinary calcium and hydroxyproline excretions), whereas only the higher dose and a treatment period of 4 months produced a reduction of bone formation (serum osteocalcin). The bone mineral content (BMC) of the nondominant forearm was unchanged. Treatment with calcitonin also had significant, dosedependent, analgetic effects. The amelioration of pain was, in multivariate analyses, related to a reduction in parameters felt to be markers for bone resorption. In the placebo group there was a significant reduction of the BMC of the forearm but no changes of any of the biochemical markers for bone turnover and no improvement of pain. In conclusion, treatment with two low doses of calcitonin induced changes of the biochemical markers of bone turnover in a dosedependent manner. The analgetic properties of calcitonin were also of salient clinical importance. The knowledge derived from this study could be adapted to the dosage schedule in long-term trials in osteoporosis.

Key words

Calcitonin Osteoporosis Biochemical markers Analgesia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Austin LA, Heath H III. (1981) Calcitonin: physiology and patophysiology. N Engl J Med 304:269–278PubMedCrossRefGoogle Scholar
  2. 2.
    Hurley DL, Tiegs RD, Wahner HW, Heath H III (1987) Axial and appendicular bone mineral density in patients with longterm deficiency or excess of calcitonin. N Engl J Med 317:537–541PubMedCrossRefGoogle Scholar
  3. 3.
    Gennari C, Chierichetti SM, Piolini M, Vibelli C, Agnusdei D (1985) Analgesic activity of salmon and human calcitonin against cancer pain: a double-blind placebo-controlled clinical study. Curr Ther Res 38:298–308Google Scholar
  4. 4.
    MacIntyre I, Stevenson JC, Whitehead MI, Wimalawansa SJ, Banks LM, Haly MJR (1988) Calcitonin for prevention of postmenopausal bone loss. Lancet i:900–902CrossRefGoogle Scholar
  5. 5.
    Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, Lambelin P, Franchimont P (1987) 1-year controlled trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet ii:1481–1483CrossRefGoogle Scholar
  6. 6.
    Fatourechi V, Heath III (1987) Salmon calcitonin in the treatment of postmenopausal osteoporosis (Editorial). Ann Int Med 107:923–925PubMedGoogle Scholar
  7. 7.
    Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH III (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295–303PubMedCrossRefGoogle Scholar
  8. 8.
    Gennari C, Chierichetti SM, Bigazzi S, Fusi L, Gonnelli S, Ferrara R, Zacchei F (1985) Comparative effects on bone mineral content of calcium and calcium plus calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 38:455–464Google Scholar
  9. 9.
    Mazzuoli GF, Passeri M, Gennari C (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled doubleblind clinical study. Calcif Tiss Int 38:3–8CrossRefGoogle Scholar
  10. 10.
    Aloia JF, Vaswani A, Kapoor A, Yeh K, Cohn SH (1985) Treatment with calcitonin with or without growth hormone. Metabolism 34:129–134CrossRefGoogle Scholar
  11. 11.
    Eriksen EF (1986) Normal and pathological remodelling of human trabecular bone: three-dimensional reconstruction of the remodelling cycle in normals and in metabolic bone disease. Endocr Rev 7:379–408PubMedCrossRefGoogle Scholar
  12. 12.
    Westlin NE (1974) Loss of bone mineral after Colles' fracture. Clin Orthop 102:194–199PubMedCrossRefGoogle Scholar
  13. 13.
    Fischer JA, Tobler PH, Henke H, Tschopp FA (1983) Salmon and human calcitonin-like peptides coexist in the human thyroid and brain. J Clin Endocrinol Metab 57:1314–1316PubMedCrossRefGoogle Scholar
  14. 14.
    Fraioli F, Fabbri A, Gnessi L, Moretti C, Santoro C, Felici M (1982) Subarachnoid injection of salmon calcitonin induces analgesia in man. Europ J Pharmacol 78:381–382CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1991

Authors and Affiliations

  • Sverker Ljunghall
    • 1
  • Per Gärdsell
    • 2
  • Olof Johnell
    • 2
  • Karin Larsson
    • 1
  • Erik Lindh
    • 1
  • Karl Obrant
    • 2
  • Ingemar Sernbo
    • 2
  1. 1.Department of Internal MedicineUniversity HospitalUppsalaSweden
  2. 2.Department of Orthopedic SurgeryMalmöSweden

Personalised recommendations